Overview

17-Alpha-Hydroxyprogesterone Caproate in Pregnant Women With Placenta Previa

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Purpose to evaluate the effects of intramuscular 17-Alpha-Hydroxyprogesterone Caproate (17-OHPC) for prevention of Emergent Cesarean Delivery in symptomatic Pregnant Women with Placenta Previa
Phase:
N/A
Details
Lead Sponsor:
Aswan University Hospital
Treatments:
11-hydroxyprogesterone
17-alpha-hydroxy-progesterone caproate